P. Valk

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

E. Vellenga, M. Jongen‐Lavrencic, L. Michaux, 2020, Leukemia.

SIRPα is downregulated in AML subsets and generates pro-apoptotic signals in t(8;21) AML

P. Kearns, C. Zwaan, G. Kaspers, 2011 .

Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia

H. Beverloo, J. Cornelissen, P. Valk, 2009, Leukemia.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

E. Vellenga, M. Fey, M. Jongen‐Lavrencic, 2014, Leukemia.

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

E. Vellenga, F. Baron, G. Meloni, 2016, Leukemia.

MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia

G. Schuurhuis, F. Kavelaars, L. Smit, 2016, Leukemia.